On Tuesday, EF Hutton maintained its Buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH), with a price target of $7.00.
The firm's stance comes after the biopharmaceutical company reported positive results from a pre-clinical study targeting Alzheimer's Disease two weeks prior. The study outcomes showed a decrease in AB levels in the brain's interstitial fluid, a reduction in anxiety behavior, and enhancements in cognitive functions within the models used.
Hoth Therapeutics' recent study is a step forward in the treatment of neuroinflammation and cognitive deficits associated with Alzheimer's Disease. The data, which was announced on a Sunday two weeks ago, marks a significant development in the company's efforts to address this challenging medical condition.
"While any possible revenues from HT-ALZ are a long way off, we like the promising start," said the analyst.
The preclinical models used in Hoth Therapeutics' study have provided encouraging results. The reduction of AB levels is a noteworthy finding, as these protein fragments can clump together to form plaques that are a hallmark of Alzheimer's Disease. The study also noted improvements in the models' cognitive functions, which are often impaired in individuals suffering from Alzheimer's.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.